SOURCE: Novo Nordisk A/S

June 13, 2008 07:30 ET

Transaction in Own Shares

Reduction of the share capital and status of holding of own shares

BAGSVAERD, DENMARK--(Marketwire - June 13, 2008) - Reduction of the share capital and status of holding of own shares

(13 June 2008)

At Novo Nordisk's ordinary general meeting on 12 March 2008 it was decided to reduce the company's B share capital from DKK 539,472,800 to DKK 526,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 12,960,000 divided into 12,960,000 B shares of DKK 1.

Today, Novo Nordisk has registered the final implementation of the reduction of the share capital with the Danish Commerce and Companies Agency and cancelled nominally DKK 12,960,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 634,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 526,512,800.

Holding of own shares

In the company's stock exchange announcement no 33/2008 released on 9 June 2008 it was stated that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates as per 9 June 2008 owned 28,781,920 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 28,781,920 or 4.5% of the total share capital.

Since 9 June 2008 a total of 192,000 B shares have been repurchased by Novo Nordisk A/S, and 70 B shares have been disposed of to employees who have exercised options granted by Novo Nordisk.

Following the cancellation of nominally DKK 12,960,000 (12,960,000 shares) of the company's own B shares and pursuant to Section 28 of the Danish Securities Trading Act, it is hereby announced that Novo Nordisk A/S and its wholly-owned affiliates as per 13 June 2008 own 16,013,850 of its own B shares. This corresponds to a total nominal value of DKK 16,013,850 B shares or 2.5 % of the total share capital.

The reduction in the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com. Further information:

Media:                 Investors:

Outside North America: Outside North America:
Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919
ekh@novonordisk.com    mlau@novonordisk.com

                       Hans Rommer
                       Tel: (+45) 4442 4765
                       hrmm@novonordisk.com

In North America:      In North America:
Sean Clements          Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com   cqfr@novonordisk.com

Stock Exchange Announcement no 35 / 2008

Copyright © Hugin AS 2008. All rights reserved.

Contact Information